Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Epitalon (Epithalon)

Cat 2 → Pending Cat 1

Longevity & Immune · Research peptide (multiple suppliers)

Synthetic tetrapeptide researched for telomerase activation and pineal gland function. Not FDA-approved for any indication.

About

Mechanism

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of epithalamin. Activates telomerase, the enzyme responsible for maintaining telomere length. May promote pineal gland function and melatonin production.

Half-Life

Estimated 1-2 hours

Route

subcutaneous

Frequency

Daily in 10-day cycles

Clinical Dosing

5-10 mgdaily in 10-day cycles

Not FDA-approved. Research on telomerase activation primarily from Russian institutes. Currently FDA Category 2 (restricted). Pending return to Category 1.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category

Research peptide (FDA Category 2)

Reclassification

pending

Date Restricted

2023-09-29

Announced Return

2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Cycling Protocol

Source: Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003

Dose	Duration	Draw (10 mg vial in 2mL)	Notes
10 mg	2 weeks	2.00 mL (200 units)	10-day cycle, then break. Repeat 2-3x/year

Available Vial Sizes

10 mg

10 mg vial

20 mg

20 mg vial

50 mg

50 mg vial

Citations

[1]Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine, 135(6), 590-592. Link(Reviewed: 2026-02-27)